MedicationMaintenance dosingMechanism of actionWeight loss relative to placeboStudy durationAdverse effectsContraindications*Approved by U.S. Food and Drug Administration
  • Liraglutide (Saxenda)

  • 0.6, 1.2, 1.8, 2.4, or 3 mg per day subcutaneously

  • Glucagon-like peptide-1 receptor agonist

  • 1.2 mg: 4.6 lb (2.1 kg)

  • 1.8 mg: 6.2 lb (2.8 kg)

  • 2.4 mg: 7.7 lb (3.5 kg)

  • 3 mg: 9.7 to 13 lb (4.4 to 5.9 kg)

  • 20 to 56 weeks

  • Abdominal pain, constipation, decreased appetite, diarrhea, dizziness, fatigue, headache, hypoglycemia, increased lipase levels, nausea, vomiting

  • Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2

  • 2014

  • Lorcaserin (Belviq)

  • 10 mg two times per day

  • 5-HT2C receptor agonist

  • 7 lb (3.2 kg)

  • One to two years

  • Back pain, constipation, cough, dizziness, dry mouth, fatigue, headache, hypoglycemia, nausea

  • 2012

  • Naltrexone/bupropion (Contrave)

  • Two 8/90-mg tablets two times per day

  • Opioid antagonist/aminoketone antidepressant

  • 16 mg: 7.7 lb

  • 32 mg: 10.4 to 10.8 lb (4.7 to 4.9 kg)

  • 56 weeks

  • Constipation, diarrhea, dizziness, dry mouth, headache, insomnia, nausea, vomiting

  • Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptics; anorexia nervosa; bulimia; long-term opioid use; seizure disorder; uncontrolled hypertension; use of a monoamine oxidase inhibitor within 14 days

  • 2014

  • Orlistat (Xenical)

  • 60 or 120 mg three times per day

  • Lipase inhibitor

  • 60 mg: 5.5 lb (2.5 kg)

  • 120 mg: 7.5 lb (3.4 kg)

  • One to four years

  • Fecal incontinence, fecal urgency, flatus, increased defecation, oily stool

  • Cholestasis, chronic malabsorption syndrome

  • 1999

  • Phentermine/topiramate (Qsymia)

  • 7.5/46 mg per day

  • 15/92 mg per day

  • Sympathomimetic/antiepileptic

  • 7.5/46 mg: 14.8 lb (6.7 kg)

  • 15/92 mg: 19.6 lb (8.9 kg)

  • 56 to 108 weeks

  • Constipation, dizziness, dry mouth, dysgeusia, insomnia, paresthesia

  • Glaucoma, hyperthyroidism, use of a monoamine oxidase inhibitor within 14 days

  • 2012